$28.08
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
Country

US

CEO

Dr. Albert Bourla

IPO date

1944

Employees

75,000

ISIN

US7170811035

Key stats

Open

$27.73

Volume

37.11M

Market cap

$158.39B

Prev. close

$28.07

Impl / hst vl

-

Open interest

$0.00

$27.65

Day’s Range

$28.42

$23.62

52W Range

$28.75

Valuation

38
Valuation score
Overvalued
P/E
35.19
P/S
2.39
P/B
1.79
Current ratio
1.27
Debt / Equity
0.74
ROE
4.89%
Gross margin
75.69%
Income growth
-109.23%
FCF growth
-86.19

Sep

1

Dividends

The last payment date was Sep 1, 2026

Div. per Share

$0.43

Div. Yield

1.55%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Hold

The average rating from top 20 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$29.15
The top 31 analysts forecasts that 12-month price may increase by 3.81%, with a low of $24.24 and a high of $37.23
$24.24
Low
$29.15
Avg
$37.23
High
Current price

Earnings

Q2 ‘26 revenue
$15.03B
Q2 ‘26 net income
-$248.00M
Revenue
Net income
Previous EPS
$0.75
Estimate EPS
$0.69
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply